



## Editorial Board Members' Collection Series in Drug Discovery

Guest Editors:

**Dr. Jean A. Boutin**

Institut de Recherches  
Internationales Servier, Suresnes,  
France

**Prof. Dr. Fabio Altieri**

Department of Biochemical  
Sciences "A. RossiFanelli", La  
Sapienza University, 00185 Rome,  
Italy

**Dr. Amirata Saei Dibavar**

Centre for Translational  
Microbiome Research,  
Department of Microbiology,  
Tumor and Cell Biology,  
Karolinska Institutet, 171 65  
Stockholm, Sweden

### Message from the Guest Editors

Dear Colleagues,

We are pleased to announce this collection entitled "Editorial Board Members' Collection Series: Drug Discovery". This issue will be a collection of papers by researchers invited by the Editorial Board Members. The aim is to provide a venue for networking and communication between *Biomedicines* and scholars in the field of drug discovery. All papers will be fully open access upon publication after peer review.

Dr. Jean A. Boutin

Prof. Dr. Fabio Altieri

Dr. Amirata Saei Dibavar

*Guest Editors*

Deadline for manuscript  
submissions:

**closed (31 October 2023)**





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)